The recommended duration of therapy is not established, though it is reasonable to treat patients until cultures are documented as negative. Antimycobacterials - Empiric antimycobacterial therapy must be comprehensive. Very active drug for nontuberculous mycobacterial disease, but acquired resistance from monotherapy is a concern. Diffuses into actively growing mycobacterial cells and impairs cell metabolism by inhibiting synthesis of 1 or more metabolites, which in turn causes cell death. No cross-resistance demonstrated.
Mycobacterial resistance is frequent with previous therapy.
Use in these patients in combination with second-line drugs that have not previously been administered. Administer qd until permanent bacteriological conversion and maximal clinical improvement is seen. Absorption not significantly altered by food. Pregnancy B - Usually safe but benefits must outweigh the risks. For treatment of mycobacteria in combination with rifampin and other antituberculosis agents.